What is the current stock price of MedinCell S.A. (MDCLF)?

As of the latest market data, MedinCell S.A. (MDCLF) is trading at $34.39. The stock has seen a loss of 0.00% today.

Does MedinCell S.A. (MDCLF) pay a dividend?

Based on current data, MedinCell S.A. does not have a confirmed active dividend policy.

What is the market cap of MedinCell S.A.?

The current market capitalization of MedinCell S.A. (MDCLF) is approximately unavailable.

MDCLF

MedinCell S.A.·Healthcare

34.39

0.000%(+0.00)

Close Price

Last Updated: — ET

52W L: $6.9852W H: $34.39

MDCLF NEWS

businesswire.com

1d ago

Medincell to Participate in Jefferies and Evercore Investor Conferences in the U.S. in June

MONTPELLIER, France--(BUSINESS WIRE)--Regulatory News: Medincell (Euronext Paris: MEDCL), a commercial- and clinical-stage biopharmaceutical licensing company developing long-acting injectable treatments, today announced that Christophe Douat, Chief Executive Officer, and Grace Kim, Chief Strategy Officer, U.S. Finance, will participate in the following leading U.S. investor conferences: Jefferies Annual NY Biotech Conference Dates: June 2-4, 2026 Location: New-York Presentation: 9:55 AM ET Jun.

seekingalpha.com

May 12

MedinCell S.A. (MDCLF) Discusses Long-Acting Injectable Platform, R&D Strategy, and Value Creation Approach Transcript

businesswire.com

Apr 16

Medincell to Host an Online R&D Day on Tuesday, May 12, 2026

MONTPELLIER, France--(BUSINESS WIRE)--Regulatory News: Medincell (Euronext Paris: MEDCL) will host an online R&D Day, held in English, on Tuesday, May 12, 2026, from 4:00 to 5:30 pm CEST (10:00 - 11:30 am ET / 7:00 - 8:30 am PT). The webcast will cover Medincell's Long‑Acting Injectable technologies, R&D execution, pipeline strategy, partnership model, and the approach to protecting and managing proprietary technologies and know‑how. The live webcast of the event and the presentation ma.

Company Profile

MedinCell S.A. develops various therapeutic solutions. It develops solutions based on BEPO, a technology for long-acting injectable products based on proprietary copolymers and a biocompatible solvent, which solubilizes or suspends the active pharmaceutical ingredients. The company's products in development include mdc-IRM, a subcutaneous injection in Phase III trials for use in the treatment of schizophrenia; mdc-CWM, an intra-articular injection to treat pain and inflammation; and mdc-TJK, a subcutaneous injection in preclinical trials for use in the treatment of schizophrenia. Its product candidates in formulation research comprise subcutaneous injections, such as mdc-WWM for contraception; mdc-ANG for CNS related treatments; mdc-ELK for depression; and mdc-GRT for use in organ transplant, as well as perineural injections, including mdc-CMV for anesthesia and pain, and mdc-NVA for pain. The company is based in Jacou, France.

Sector

Healthcare

Industry

Biotechnology

Employees

131

IPO Date

2021-01-05

Beta

1.00

Websitewww.medincell.com↗